Nitric oxide-donor/PARP-inhibitor combination: A new approach for sensitization to ionizing radiation

Recently, clinical development of PARP inhibitors (PARPi) expanded from using them as a single agent to combining them with DNA-damaging therapy to derive additional therapeutic benefit from stimulated DNA damage. Furthermore, inhibiting PARP in cancers with BRCA1/2 mutations has been shown to be an...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Redox Biol
Egile Nagusiak: Wilson, Aaron, Menon, Vijay, Khan, Zubair, Alam, Asim, Litovchick, Larisa, Yakovlev, Vasily
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Elsevier 2019
Gaiak:
Research Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6423503/
https://ncbi.nlm.nih.gov/pubmed/30889466
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.redox.2019.101169
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak